No Data
No Data
Changchun High-Tech Industries (000661.SZ): The clinical trial application for the type II simple herpes virus mRNA vaccine of the controlled subsidiary has been approved.
Gelonghui reported on December 20 that Changchun High-Tech Industries (000661.SZ) announced that its holding subsidiary - Changchun Baike Biotechnology Co., Ltd. (hereinafter referred to as "Baike Biotechnology") has received the approval notice for drug clinical trials issued by the National Medical Products Administration. The clinical trial application for the Type II herpes simplex virus mRNA vaccine has been approved. Type II herpes simplex virus infection, which leads to genital herpes, is a contagious disease primarily spread through sexual contact, characterized by easy transmission, recurrence, and a lack of effective cure, becoming a serious public health issue. To prevent the occurrence of genital herpes, already several...
Express News | Changchun High-Tech Industries: The clinical trial application for the type II simplex herpes virus mRNA vaccine by the holding subsidiary has been approved.
Changchun High-Tech Industry's Unit Gets Registration Certificate for Luteinizing Hormone Kit
Express News | Changchun High-Tech Industries: The subsidiary Shanghai Saizeng Medical Technology Co., Ltd. has obtained the medical instruments registration certificate.
Express News | Changchun High-Tech Industries: Promoting the luteinizing hormone detection kit has received the medical instruments registration certificate.
Changchun High-Tech Industry's Unit Gets Nod to Trial Advance Solid Tumors Treatment Tablets
No Data